CYCC: Cyclacel Pharmaceuticals Inc Company Profile & Statistics

About

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

Info & Links

CEO

Spiro Rombotis

Headquarters

200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS, NJ 07922, UNITED STATES

Auditor

RSM US LLP

Share holders

Employees

Cyclacel Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization²

2.20M

Enterprise Value

-780.50K

Enterprise Value/EBITDA(ttm)

0.05

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

30.68

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-18150.00%

Profit Margin(ttm)

-32080.34%

Return on Equity(ttm)

-1901.11%

Return on Invested Capital(ttm)

-859.10%

Return on Assets(ttm)

-188.23%

Income Statement

Revenue(ttm)

74.00K

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

74.00K

EBITDA(ttm)³

-15.52M

Net Income Available to Common(ttm)

-13.48M

Diluted EPS(ttm)

-9.40

Share Statistics

Beta (5Y Monthly)

0.38

52-Week Change

-92.04%

S&P 500 52-Week Change

25.73%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

6.29M

Dividend Yield

0.00%

Float⁴

5.78M

% Held by Insiders

8.00%

% Held by Institutions

23.58%

Balance Sheet

Total Cash(mrq)

2.98M

Total Cash Per Share(mrq)

0.47

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

0.77%

Quick Ratio(mrq)

0.77%

Book Value Per Share(mrq)

-0.45

Cash Flow

Operating Cash Flow Per Share(ytd)

0.61

Free Cash Flow(ytd)

-6.63M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CYCC

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc Profile